(21) reported that CD4+ T cells recovered slower in HID HSCT recipients compared with those receiving HLA matched donor HSCT, which may be due to the use of ATG for GVHD prophylaxis (47, 48). The gene discussed is CD4; the disease is graft versus host disease.